美国胃肠病学会轻度至中度溃疡性结肠炎管理技术综述
本技术综述由美国胃肠病学会根据推荐分级的评估、制定与评价框架制定,旨在为轻度至中度溃疡性结肠炎临床指南提供依据。综述聚焦5-氨基水杨酸制剂比较、给药方案与途径、口服布地奈德、直肠制剂及替代疗法等关键问题。
要点
- 轻度至中度溃疡性结肠炎患者疾病活动度低、结肠切除风险低,常由基层医生或消化科医生管理。
- 不同口服5-氨基水杨酸制剂、剂量、给药方案及途径存在较大实践差异。
- 本综述围绕5-氨基水杨酸比较、布地奈德、直肠制剂及益生菌等替代疗法展开证据评价。
核心结论
- 本技术综述按推荐分级的评估、制定与评价框架开 展,为美国胃肠病学会轻度至中度溃疡性结肠炎临床指南提供依据。
研究设计与样本
- 本技术综述依据推荐分级的评估、制定与评价框架对干预性研究进行系统评价。
关键数值与推荐
- 重点问题包括不同口服5-氨基水杨酸制剂(柳氮磺吡啶 vs 偶氮键5-氨基水杨酸 vs 美沙拉秦)的比较效果与耐受性。
- 重点问题包括美沙拉秦低剂量(<2 g)vs 标准剂量(2-3 g/d)vs 高剂量(>3 g/d)的比较效果与耐受性。
- 重点问题包括不同给药方案(每日一次 vs 每日多次)和途径(口服 vs 直肠 vs 口服联合直肠)的比较。
- 重点问题包括口服布地奈德在轻度至中度溃疡性结肠炎中的作用。
- 重点问题包括直肠5-氨基水杨酸与皮质类固醇制剂在远端结肠炎中的比较效果与耐受性,以及益生菌、姜黄素和粪菌移植等替代疗法的作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with ulcerative colitis (UC) have mild-to-moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists. Optimal management of these patients decreases the risk of relapse and proximal disease extension, and may prevent disease progression, complications, and need for immunosuppressive therapy. With several medications (eg, sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budesonide) and complex dosing formulations, regimens, and routes, to treat a disease with variable anatomic extent, there is considerable practice variability in the management of patients with mild-moderate UC. Hence, the American Gastroenterological Association prioritized clinical guidelines on this topic. To inform clinical guidelines, this technical review was developed in accordance with the Grading of Recommendations Assessment, Development and Evaluation framework for interventional studies. Focused questions included the following: (1) comparative effectiveness and tolerability of different oral 5-ASA therapies (sulfalsalazine vs diazo-bonded 5-ASAs vs mesalamine; low- (<2 g) vs standard (2-3 g/d) vs high-dose (>3 g/d) mesalamine); (2) comparison of different dosing regimens (once-daily vs multiple times per day dosing) and routes (oral vs rectal vs both oral and rectal); (3) role of oral budesonide in patients mild-moderate UC; (4) comparative effectiveness and tolerability of rectal 5-ASA and corticosteroid formulations in patients with distal colitis; and (5) role of alternative therapies like probiotics, curcumin, and fecal microbiota transplantation in the management of mild-moderate UC.
引用
- Singh S, Feuerstein JD, Binion DG, et al. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2018. PMID: 30576642. doi:10.1053/j.gastro.2018.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。